Vaccine Adjuvant Market Size, Share, By Product Type (Particulate Adjuvants, Emulsion Adjuvants, Pathogen Adjuvants, Combination Adjuvants, and Other Adjuvants), By Route of Administration (Oral, Intranasal, Intramuscular, Subcutaneous, Intradermal, and Others), By Disease Type (Cancer, Infectious Disease, and Others), By Application (Research, Commercial, and Others), and By Region - Trends, Analysis and Forecast till 2034

Vaccine Adjuvant Market Size was valued at USD 2.2 Billion in 2024 and is expected to reach USD 6.4 Billion by 2034, growing at a CAGR of 13.0%

The adjuvant vaccine market holds a lot of promise due to several factors. First and foremost is the deep realization that an adjuvant makes all the difference in a vaccine's effectiveness. This sentiment is reflecting in huge R&D investments. It classically leads to the creation of a new generation of adjuvants, characterized by being safe but highly effective, thus leading to more robust vaccines. Furthermore, it is alarming to learn that chronic infectious diseases are increasing worldwide. There is an enormous unmet medical need for improved vaccines, and adjuvants will, without any doubt, become an integral part of this challenge. Adjuvants can substantially improve immune responses to new and mostly complex pathogens and increase the efficacy of vaccines against chronic diseases. Adding further momentum to the market is the growing government support in terms of funding toward R&D initiatives for vaccine adjuvants. This would accelerate the pace of development and commercialization process of novel adjuvants with greater public funding. This would not only help the general public health but also boost the market. Besides, market players are entering into collaboration through mergers, acquisitions, and partnerships. This strategic approach increases not only the speed of product launches but also the width of the product portfolio in the marketplace. With combined resources and skills, it gives a boost to innovation and shortens time-to-market for new adjuvants.

The road ahead is, however, unfortunately not so easy. Tight regulation on policy—the very thing that is important for safety and efficacy—can itself sometimes be a barrier through delayed approvals for new adjuvants. Not only does it act to stifle innovation, but it delays the availability of lifesaving vaccines. Again, the challenge comes in the way of high production costs and intrinsic complexities in the manufacturing process. These two are the significant deterrents to the pervasive application of adjuvants in general, more so within the resource-poor settings. Finally, the question of safety keeps lurking. Possible side effects due to adjuvants call for constant monitoring and further research studies. Allaying these fears and creating confidence among people will hold the key to continued market growth. Conclusion The vaccine adjuvant market holds immense potential driven by recognition of the critical role adjuvants play in developing next-generation vaccines. This very promising market, therefore, will fall into the hands of companies that can better navigate this regulatory labyrinth, manage production costs, and ensure long-term safety.

Key Drivers of Target Market:

Increase in R&D Investments

• The pharmaceutical industry is trending towards adjuvants. Knowing very well the potentials of adjuvants in effectively enhancing vaccine efficacy, major players are pouring money into research and development. In some ways, this has opened up doors for creating a new breed of adjuvants that will be safe and highly effective. This will, in turn, mean a much wider bank of adjuvants tailored for special vaccines and pathogens, resulting in more robust and focused immunization programs.
• The current global health situation is saddled with the onslaught of chronic infectious diseases. These newly emerging and frequently complicated pathogens greatly challenge the process of developing vaccines against such pathogens. Here is where adjuvants become prominent players, as they hold the key to efficiently improving the immune response directed against pathogens. Having increased the body's capacity for identification and fighting against such chronic infections, adjuvants play a very critical role in developing more efficient vaccines for improved health outcomes among the public.

Government Funding towards Innovation

• Governments across the world have developed a realization of the paramount role vaccines and adjuvants play in global health security. It means increased public funding towards R&D activities on vaccine adjuvants. Such financing not only accelerates the process of development and commercialization of novel adjuvants but also supports market growth. Financial support provided to innovation in this critical area will help countries ensure that citizens get access to life-saving vaccines in time.
• The vaccine adjuvant market is trending increasingly toward collaboration between industry players. Companies enter into mergers, acquisitions, and partnerships for the setting up of a collaborative environment. This will advantage them in many ways: by making it possible to pool resources and expertise that can eventually bring products to market faster and increase the breadth of product portfolios in the market. Finally, such collaboration will allow sharing knowledge and cross-pollination of ideas for adjuvants, increasing the speed of innovation and their development.

Restrains:

Stringent Regulatory Requirements

• Coupled with the policy on adverse events, these could pose a major challenge to the vaccine adjuvant market. Broadly, the licensing procedure for new adjuvants is very cumbersome and time-consuming, requiring rigorous testing and evaluation for safety and efficacy. This may retard innovation and delay the availability of vaccines that have the potential to save human lives. Developers of novel adjuvants have to navigate a maze of regulatory hurdles, and this can substantially impact companies' timelines and financial resources.
• Adjuvant manufacture is an expensive and complex process for vaccine production. This activity involves a lot of production procedures that require special equipment and rich expertise, which increases the cost of the overall production process. This might set a barrier to a large diffusion of adjuvants, mostly in resource-limited settings. Moreover, intrinsic manufacturing complexities may challenge the quality homogeneity and scaling up to market demand.

Safety Concerns and Public Perception

• Despite elaborate testing, the possible side effects associated with adjuvants are a concern. While most adjuvants are normally well-tolerated, some may cause mild or moderate side effects. This puts the public on their guard against the vaccines containing adjuvants. This basically means that for long-term growth, continuous efforts are required to allay such safety concerns and to put in place public confidence in the safety and effectiveness of adjuvants. In fact, this will call for perpetual research and open communication to help retain public trust in this vital technology.
• Some adjuvants, like those prepared from shark liver oil, raise ethical concerns. Mass production of such adjuvants has the risk of posing a threat to the species. There is an urgent need for developing alternative adjuvants that are either plant-based or synthetic in nature to address these ethical concerns and ensure long-term, sustainable growth in the market.

Opportunities:

Adjuvants for chronic diseases

• The burden from chronic infectious diseases, like HIV and malaria, is increasingly being felt; this provides a very good opportunity for adjuvant development. It is often the case that the complex pathogen requires a stronger and more specific immune response than that which conventional vaccines are capable of bringing out. The adjuvants developed to specifically focus on these chronic diseases might be a real game-changer in the development of more potent vaccines and improvement of population health outcomes related to these very diseases.

Expanding applications in non-infectious diseases

• Despite their current application in infectious diseases, adjuvants can have much more extended scope.  Presently, researches are underway to utilize adjuvants against cancer, allergies, and autoimmune disorders.  Provided the safety and efficiency of adjuvants are established in these spheres, they will be a huge potential market.

Geographical Expansion

• The vaccine adjuvant market is currently focused in the developed regions. However, there exists huge potential for growth in the emerging markets where vaccination programs are currently in action and disposable incomes on the rise.  Developing cost-effective production methods and forming a partnership with the local companies will help get a foothold into these markets.

Focus on Patient Education and Public Awareness

• Communicating and educating the public on the safety of adjuvants itself has huge potential for reverting benefits to the market. Building trust and creating transparency will provide the setting in which the general public is more accepting of vaccines with adjuvants, hence increasing the market size for these critical technologies.

The market is segmented based on By Product Type, By Route of Administration, By Disease Type, By Application, and Region.

By Product Type Insights:

• Particulate adjuvants are the sirens that prompt the immune system to get the attention of antigen-presenting cells that help start an immune response. Aluminum salts lead the way and end up in most present vaccines. They are so successful because, all the while stimulating the immune system, they do not cause huge side effects.
• Emulsion adjuvants: Take an oil-in-water mixture as a slow-release capsule for antigens—essentially what emulsion adjuvants do. They provide a depot effect in the injected site, allowing gradual antigen release over some time and thus more sustained and potent immune responses. It is this sort of controlled release that makes them especially useful in vaccines such as those against influenza, shingles, and HPV, among others, in which long-term immunity may be desired.
• Pathogen-Derived Adjuvants: These adjuvants merely take a leaf out of the pathogen's book. They make use of fragments from the bacterial cell wall or parts of the virus that stimulate the immune system directly, which has been mimicked by an actual infection. Nevertheless, due to the safety concerns linked with the application of such pathogen-based material, its usage is more limited compared to other forms of adjuvants.
• Combination Adjuvants: The name itself tells us that this has been combined with the power of two or more dissimilar adjuvant types. Combination adjuvants hit different parts of the immune system and can turn out to produce a more efficient and subtle immune response than single adjuvants. This approach is one of the strategic directions which may potentially enhance the efficacy of vaccines against complex pathogens.
• Other adjuvants: The adjuvant landscape is changing and many other promising candidates are being investigated. Liposomes are microscopic spheres resembling cell membranes being studied for their potential to take antigens more effectively. Immunostimulatory oligonucleotides are short stretches of synthetic DNA constituting another exciting avenue of study because they have the potential to directly activate immune cells. Cytokines are being investigated for their ability to modulate vaccine-elicited immune responses, being natural immune system signaling molecules.

By Route of Administration Insights:

• Oral vaccines have the advantages of ease of administration and the ability to induce mucosal and systemic immunity. However, the bad conditions within the digestion tract are very harsh on adjuvants. Now, only a few adjuvants, like live attenuated bacteria used in some oral vaccines themselves, could pass through the digestion tract and play a role in enhancing the immune response effectively. Therefore, new adjuvants specially designed for oral vaccines are under development.
• Intranasal: This route has the potential to provoke both mucosal and systemic immunity and is, therefore, attractive for respiratory tract infections. Similar challenges to those found with oral administration exist with adjuvant stability in the nasal cavity. Investigation is being conducted on adjuvants like liposomes and nanoparticles, which efficiently deliver antigens together with adjuvants through the intranasal route.
• Intramuscular: This is the most common route of administration for injectable vaccines. A wide range of adjuvants, from aluminum salts to emulsions and some immunostimulatory molecules, may be compatible with an IM injection. In such conditions, IM injection readily becomes a versatile option for many vaccines due to its relative ease of administration and robustness of the elicited immune response.
• Subcutaneous: Much like intramuscular injections, subcutaneous injections are a very convenient and efficient vaccine administration route. Indeed, one can employ a wide range of adjuvants with SC administration, including aluminum salts and a variety of emulsions. This route is often favored when a slower release of the antigen into the bloodstream is desirable, which would occur more rapidly after an intramuscular injection.
• Intradermal: This route holds out the promise for a more focused immune response at possibly lower antigen doses. Administering ID injections requires special training of the health professional, and this route may not be as easily embraced as other routes. Some adjuvant candidates under study for ID administration include aluminum salts and immunostimulatory sequences.
• Others include less common routes, like transdermal and pulmonary delivery, under study as methods of administration for vaccines. Research into adjuvants compatible with alternative routes of administration is active and holds great potential to expand vaccine delivery options and improve patient compliance.

By Disease Type Insights:

• Cancer: This segment is rapidly growing due to the increasing incidence of cancer and an increased focus on developing therapeutic cancer vaccines. Adjuvants hold a key contribution in eliciting immune response to recognize and attack cancer cells. Research is ongoing for the development of adjuvants to be tailored for enhancing the effectiveness of cancer vaccines.
• Infectious Diseases: This segment currently has the largest market share and is expected to continue dominating the global adjuvants market in the future. The following factors will contribute to this: The persistent threat of infectious diseases, like influenza, HPV, and HIV, necessitates continuous development and upgrading of vaccines against them. Adjuvants can enhance the efficacy of vaccines against such pathogens; therefore, an enhanced and more durable immune response after vaccination can be elicited. Enhanced vaccination programs globally increase the demand for adjuvants used in infectious disease vaccines.
• Others: This is a more extended set of possibilities that includes: Adjuvants can be used for immunoregulation and, hence in the treatment of autoimmune disorders. Adjuvants can be used to develop allergy vaccines that would desensitize the immune system to particular allergens.

By Application Insight

• Research: This represents the development and testing of new adjuvants. Major players in this area are research institutions, biotech companies, and academic laboratories. These industries are catered to by the research-grade adjuvants market, which provides niche adjuvants for pre-clinical studies.
• Commercial: This segment comprises adjuvants used in commercially available vaccines. Pharmaceutical companies developing and manufacturing vaccines either for human or veterinary uses are totally dependent upon commercially available adjuvants which have passed several tests and regulatory approvals.
• Others: The other areas which adjuvants can be applied to in the future include:

o   Adjuvants for biodefense vaccines: Vaccines against potential agents of bioterrorism may be developed with the use of adjuvants to generate efficient immune responses.

o   Future Directions on Adjuvants for Personalized Medicine: Tailoring adjuvants according to the specific immune response would be an area of personalized vaccine research.

Regional Insights

• North America: This region holds the greatest market share at the moment, and the contributory factors towards it are as follows: A high presence of key pharmaceutical and biotech companies involved in adjuvant development and manufacturing processes for vaccines. Well-established healthcare infrastructure with huge investments in R&D for vaccine adjuvants. High awareness among the general public and acceptance of vaccination programs.
• Europe dominates the vaccine adjuvant market, with a strong research and development orientation. This is represented by the following key features: rigorous regulatory environments that control the approval of vaccines and adjuvants; increasing emphasis on preventive care and government promotion for vaccination programs; and major academic institutions and research centers working on adjuvant development.
• Asia-Pacific: The vaccine adjuvant market will grow at the fastest rate in this region owing to the following factors: Economies are rapidly growing, and disposable income is increasing. Vaccination demand on account of large and expanding populations. Growing focus on government immunization programs and public health initiatives.
• Latin America represents an emerging vaccine adjuvants market propelled by increasing government investments in healthcare infrastructure and vaccination programs, rising awareness about vaccination as social insurance for public health, and the large and growing population with a significant unmet medical need for vaccines.
• Middle East and Africa: which means that it is a region that is at once challenging and potential for a vaccine adjuvants market. Part of this region is badly off in resources and health infrastructure. International organizations are backing efforts to build immunization programs. Investment towards research and development in vaccines is increasing within the region itself.

Vaccine Adjuvant Market Report Scope:

Attribute	Details
Market Size 2024	USD  2.2 Billion
Projected Market Size 2034	USD  6.4 Billion
CAGR Growth Rate	13.0%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD  Billion & CAGR from 2024 to 2034
Market Segmentation	By Product Type- Particulate Adjuvants, Emulsion Adjuvants, Pathogen Adjuvants, Combination Adjuvants, and Other Adjuvants By Route of Administration- Oral, Intranasal, Intramuscular, Subcutaneous, Intradermal, and Others By Disease Type- Cancer, Infectious Disease, and Others By Application- Research, Commercial, and Others
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on By Product Type, By Route of Administration, By Disease Type, By Application, and Region.

By Product type:

• Particulate Adjuvants
• Emulsion Adjuvants
• Pathogen Adjuvants
• Combination Adjuvants
• Other Adjuvants

By Route of Administration:

• Oral
• Intranasal
• Intramuscular
• Subcutaneous
• Intradermal
• Others

By Disease Type:

• Cancer
• Infectious Disease
• Others

By Application:

• Research
• Commercial
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Vaccine Adjuvant Market include SEPPIC Inc., Novavax, Inc., Hayashibara Co., Ltd., SPI Pharma Inc, Invivogen, Avanti Polar Lipids, Inc., MPV Technologies, OZ Biosciences, Agenus,Inc., Brenntag Biosector, Spectrum Pharmaceuticals. Inc., Sigma Aldrich, Adjuatis, Vaxliant, Adjuvance Technologies, Inc., GlaxoSmithKline plc., Puma Biotechnology, Tj Kaiwei, Zhouyue, Aphios, and CSL Limited.

• In January 2023, Elicio Therapeutics, which is innovating in lymph node-targeted adjuvants and vaccines against a variety of aggressive cancers and infectious diseases, has entered into a definitive agreement to merge with Angion Biomedica Corp for the continued development of Elicio's proprietary lymph node-targeting Amphiphile (AMP) technology, with a special focus on immunotherapies, specifically ELI-002 for therapeutic cancer vaccination against mKRAS-powered tumors.
• In November 2022, Hubro Therapeutics AS is buying the GM-CSF vaccine adjuvant from Targovax ASA under an asset purchase for cash of NOK10 million. Hubro Therapeutics is further developing the GM-CSF as an adjuvant for use with its pipeline of new-to-the-world cancer vaccines.

• SEPPIC INC.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Novavax, Inc.
• Hayashibara Co., Ltd.
• SPI Pharma Inc.
• Invivogen
• Avanti Polar Lipids, Inc.
• MPV Technologies
• OZ Biosciences
• Agenus, Inc.
• Brenntag Biosector
• Spectrum Pharmaceuticals, Inc.
• Sigma Aldrich
• Adjuatis
• Vaxliant
• Adjuvance Technologies, Inc.
• GlaxoSmithKline plc.
• Puma Biotechnology
• Tj Kaiwei
• Zhouyue
• Aphios
• CSL Limited

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Product Type
  • Market Snippet, By Route of Administration
  • Market Snippet, By Disease Type
  • Market Snippet, By Application
  • Market Snippet, By Region
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, Product type, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Particulate Adjuvants
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Emulsion Adjuvants
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Pathogen Adjuvants
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

• Combination Adjuvants
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Others Adjuvants
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, Route of Administration, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Intranasal
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Intramuscular
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Subcutaneous
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Intradermal
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Disease Type, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Cancer
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Infectious Disease
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Application, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Research
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Commercial
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Region, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (USD Bn), By Product type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Disease Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • U.S
    • Canada
• Asia Pacific
  • Market Size and Forecast (USD Bn), By Product type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Disease Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Europe
  • Market Size and Forecast (USD Bn), By Product type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Disease Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • UK
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
• Latin America
  • Market Size and Forecast (USD Bn), By Product type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Disease Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Market Size and Forecast (USD Bn), By Product type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Disease Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Application, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East and Africa

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• SEPPIC Inc.
• Novavax, Inc.
• Hayashibara Co., Ltd.
• SPI Pharma Inc.
• Invivogen
• Avanti Polar Lipids, Inc.
• MPV Technologies
• OZ Biosciences
• Agenus, Inc.
• Brenntag Biosector
• Spectrum Pharmaceuticals, Inc.
• Sigma Aldrich
• Adjuatis
• Vaxliant
• Adjuvance Technologies, Inc.
• GlaxoSmithKline plc.
• Puma Biotechnology
• Tj Kaiwei
• Zhouyue
• Aphios
• CSL Limited

The Last Word

• Future Impact
• About Us
• Contact